These top growth stocks could dramatically improve your financial wellbeing.
News & Analysis: Amarin
The mid-cap drugmaker's poor start to the year could be an outstanding buying opportunity for long-term investors.
Vascepa has a good chance of being a blockbuster, but an upcoming patent decision will have the final word.
Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.
Opinions vary considerably.
All your Motley Fool coverage of the 2020 J.P. Morgan Healthcare Conference in one place.
The Super Bowl of healthcare kicked off early for these companies.
The small-cap pharma sank on an update from its top competitor.
The company gave investors some unaudited numbers from the most recent quarter on how its fish oil-derived medicine performed. And its newly expanded label means this year will be even bigger.
Exponential growth is on the horizon for these companies. Investors should take note.